CIRHIS: Cellular Human immune Responses during controlled Human malaria Infection Studies (GHDC-SI-ID-53)- cryoPBMC CyTOF Pheno

The goal of this project is to investigate whether we can use host-directed therapy (ruxolitinib) in conjunction with the anti-malarial drug artemether-lumefantrine to enhance immune responses in malaria-naïve individuals participating in a controlled human malaria infection model with P. falciparum-induced blood-stage malaria. With support from the Gates Foundation’s Collaboratory, we have generated CyTOF/mass cytometry surface phenotyping data on live cryoPBMC samples collected from study participants. The samples were stained in batches of plates. All the Early timepoints for a given study donor were stained together on the same plate. All the Late timepoints for a given study donor were stained together on a separate plate. A healthy donor QC control was included on each plate. The samples were stained and run individually (not barcoded), and were normalized in the Finck et al method using Premessa. The Beads file from the first plate was used as the normaliation reference for all subsequent plates. The files are Ungated (still contain Beads, doublets, dead cells, debris, etc).(Related dataset: WB PROT1 PhosphoCyTOF permalink: https://doi.org/10.5281/zenodo.14872945)